Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 1998

View Archived Issues

Abgenix completes phase II clinical trial in GVHD

Celltech: 1998 fiscal year-end highlights

Kinetek initiates phase I studies of type II diabetes treatment

Maxim advances development of MaxDerm topical treatment

Cell Genesys and Japan Tobacco enter worldwide collaboration for GVAX cancer vaccine

Joint clinical study results reported for Hepagene as HBV treatment

Another group of MMP inhibitors discovered at Hoechst

5'-Deoxycytidines improve delivery to tumors and antineoplastic activity of 5-FU

Orally bioavailable serine protease inhibitors for thrombotic disorders designed at Akzo

SmithKline Beecham patents combined 5-HT1A/5-HT1B/5-HT1D receptor antagonists

New cell adhesion inhibitors in development at Lilly for inflammatory disorders, etc.

New market launch for novel anticonvulsant: Topamax available in Germany

Campto launched in another major market

FDA grants fast track designation for OvaRex MAb

AxyS and Merck extend osteoporosis collaboration

Isis and Zeneca to develop novel antisense-based cancer drugs

Structure revealed by Tanabe Seiyaku for potent, orally active SGLT inhibitor

FDA approves first Lyme disease vaccine

Phase I results with GI-147211 establish MTD; phase II doses recommended

Miltefosine evaluated clinically for the oral treatment of visceral leishmaniasis

Broader indication for Agrylin approved by FDA

Previously reported anti-H. pylori cephem characterized in greater detail at recent congress

Suppression of chemokine production contributes to beneficial dermal effects of tacalcitol

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...